| Murali Veeramachaneni, MD,PA | |
|
22 Care Cir, Amarillo, TX 79124-2118 | |
| (806) 354-8300 | |
| (806) 354-9962 |
| Full Name | Murali Veeramachaneni |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 32 Years |
| Location | 22 Care Cir, Amarillo, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851374367 | NPI | - | NPPES |
| 113594902 | Medicaid | TX | |
| 113594901 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | K5023 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwest Texas Hospital | Amarillo, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Murali Veeramachaneni, M.d, P.a | 0345486130 | 2 |
News Archive
Occupational sitting is associated with an increased likelihood of obesity, especially among black women, independent of occupational and leisure time physical activity, finds a new study from the School of Medicine and the Brown School at Washington University in St. Louis.
Theresa Chang and colleagues at Mount Sinai School of Medicine analyzed how alpha-defensin-1 inhibits HIV infection in white blood cells (CD4+ T cells). Defensins have been shown to have anti-HIV activity. The body attempts to protect itself from HIV infection via the innate immune system.
With an uptick in cases of hand, foot and mouth disease in the area, Loyola Medicine pediatric infectious disease specialist Nadia Qureshi, MD, offers tips to keep kids healthy as they go back to school.
Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.
OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.
› Verified 6 days ago
| Entity Name | Bexar County Board Of Trustees For Mental Health Mental Retardation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730134586 PECOS PAC ID: 5496652760 Enrollment ID: O20031215000906 |
News Archive
Occupational sitting is associated with an increased likelihood of obesity, especially among black women, independent of occupational and leisure time physical activity, finds a new study from the School of Medicine and the Brown School at Washington University in St. Louis.
Theresa Chang and colleagues at Mount Sinai School of Medicine analyzed how alpha-defensin-1 inhibits HIV infection in white blood cells (CD4+ T cells). Defensins have been shown to have anti-HIV activity. The body attempts to protect itself from HIV infection via the innate immune system.
With an uptick in cases of hand, foot and mouth disease in the area, Loyola Medicine pediatric infectious disease specialist Nadia Qureshi, MD, offers tips to keep kids healthy as they go back to school.
Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.
OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.
› Verified 6 days ago
| Entity Name | Spindletop Mhmr Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952357550 PECOS PAC ID: 1658268321 Enrollment ID: O20040228000236 |
News Archive
Occupational sitting is associated with an increased likelihood of obesity, especially among black women, independent of occupational and leisure time physical activity, finds a new study from the School of Medicine and the Brown School at Washington University in St. Louis.
Theresa Chang and colleagues at Mount Sinai School of Medicine analyzed how alpha-defensin-1 inhibits HIV infection in white blood cells (CD4+ T cells). Defensins have been shown to have anti-HIV activity. The body attempts to protect itself from HIV infection via the innate immune system.
With an uptick in cases of hand, foot and mouth disease in the area, Loyola Medicine pediatric infectious disease specialist Nadia Qureshi, MD, offers tips to keep kids healthy as they go back to school.
Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.
OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.
› Verified 6 days ago
| Entity Name | Central Texas Mental Health And Mental Retardation Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619196169 PECOS PAC ID: 5193613446 Enrollment ID: O20040311001487 |
News Archive
Occupational sitting is associated with an increased likelihood of obesity, especially among black women, independent of occupational and leisure time physical activity, finds a new study from the School of Medicine and the Brown School at Washington University in St. Louis.
Theresa Chang and colleagues at Mount Sinai School of Medicine analyzed how alpha-defensin-1 inhibits HIV infection in white blood cells (CD4+ T cells). Defensins have been shown to have anti-HIV activity. The body attempts to protect itself from HIV infection via the innate immune system.
With an uptick in cases of hand, foot and mouth disease in the area, Loyola Medicine pediatric infectious disease specialist Nadia Qureshi, MD, offers tips to keep kids healthy as they go back to school.
Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.
OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.
› Verified 6 days ago
| Entity Name | The Gulf Coast Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245285899 PECOS PAC ID: 6204821895 Enrollment ID: O20040414001641 |
News Archive
Occupational sitting is associated with an increased likelihood of obesity, especially among black women, independent of occupational and leisure time physical activity, finds a new study from the School of Medicine and the Brown School at Washington University in St. Louis.
Theresa Chang and colleagues at Mount Sinai School of Medicine analyzed how alpha-defensin-1 inhibits HIV infection in white blood cells (CD4+ T cells). Defensins have been shown to have anti-HIV activity. The body attempts to protect itself from HIV infection via the innate immune system.
With an uptick in cases of hand, foot and mouth disease in the area, Loyola Medicine pediatric infectious disease specialist Nadia Qureshi, MD, offers tips to keep kids healthy as they go back to school.
Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.
OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.
› Verified 6 days ago
| Entity Name | Texana Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912954058 PECOS PAC ID: 7618963265 Enrollment ID: O20040421000535 |
News Archive
Occupational sitting is associated with an increased likelihood of obesity, especially among black women, independent of occupational and leisure time physical activity, finds a new study from the School of Medicine and the Brown School at Washington University in St. Louis.
Theresa Chang and colleagues at Mount Sinai School of Medicine analyzed how alpha-defensin-1 inhibits HIV infection in white blood cells (CD4+ T cells). Defensins have been shown to have anti-HIV activity. The body attempts to protect itself from HIV infection via the innate immune system.
With an uptick in cases of hand, foot and mouth disease in the area, Loyola Medicine pediatric infectious disease specialist Nadia Qureshi, MD, offers tips to keep kids healthy as they go back to school.
Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.
OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.
› Verified 6 days ago
| Entity Name | Bluebonnet Trails Community Mhmr Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730135864 PECOS PAC ID: 5799775409 Enrollment ID: O20040514000751 |
News Archive
Occupational sitting is associated with an increased likelihood of obesity, especially among black women, independent of occupational and leisure time physical activity, finds a new study from the School of Medicine and the Brown School at Washington University in St. Louis.
Theresa Chang and colleagues at Mount Sinai School of Medicine analyzed how alpha-defensin-1 inhibits HIV infection in white blood cells (CD4+ T cells). Defensins have been shown to have anti-HIV activity. The body attempts to protect itself from HIV infection via the innate immune system.
With an uptick in cases of hand, foot and mouth disease in the area, Loyola Medicine pediatric infectious disease specialist Nadia Qureshi, MD, offers tips to keep kids healthy as they go back to school.
Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.
OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.
› Verified 6 days ago
| Entity Name | Burke Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396792420 PECOS PAC ID: 1254312077 Enrollment ID: O20040527000661 |
News Archive
Occupational sitting is associated with an increased likelihood of obesity, especially among black women, independent of occupational and leisure time physical activity, finds a new study from the School of Medicine and the Brown School at Washington University in St. Louis.
Theresa Chang and colleagues at Mount Sinai School of Medicine analyzed how alpha-defensin-1 inhibits HIV infection in white blood cells (CD4+ T cells). Defensins have been shown to have anti-HIV activity. The body attempts to protect itself from HIV infection via the innate immune system.
With an uptick in cases of hand, foot and mouth disease in the area, Loyola Medicine pediatric infectious disease specialist Nadia Qureshi, MD, offers tips to keep kids healthy as they go back to school.
Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.
OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.
› Verified 6 days ago
| Entity Name | Camino Real Community Mhmr Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154411262 PECOS PAC ID: 9931183449 Enrollment ID: O20040614001095 |
News Archive
Occupational sitting is associated with an increased likelihood of obesity, especially among black women, independent of occupational and leisure time physical activity, finds a new study from the School of Medicine and the Brown School at Washington University in St. Louis.
Theresa Chang and colleagues at Mount Sinai School of Medicine analyzed how alpha-defensin-1 inhibits HIV infection in white blood cells (CD4+ T cells). Defensins have been shown to have anti-HIV activity. The body attempts to protect itself from HIV infection via the innate immune system.
With an uptick in cases of hand, foot and mouth disease in the area, Loyola Medicine pediatric infectious disease specialist Nadia Qureshi, MD, offers tips to keep kids healthy as they go back to school.
Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.
OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.
› Verified 6 days ago
| Entity Name | Texas Panhandle Mental Health Mental Retardation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134188139 PECOS PAC ID: 0446200067 Enrollment ID: O20050131000802 |
News Archive
Occupational sitting is associated with an increased likelihood of obesity, especially among black women, independent of occupational and leisure time physical activity, finds a new study from the School of Medicine and the Brown School at Washington University in St. Louis.
Theresa Chang and colleagues at Mount Sinai School of Medicine analyzed how alpha-defensin-1 inhibits HIV infection in white blood cells (CD4+ T cells). Defensins have been shown to have anti-HIV activity. The body attempts to protect itself from HIV infection via the innate immune system.
With an uptick in cases of hand, foot and mouth disease in the area, Loyola Medicine pediatric infectious disease specialist Nadia Qureshi, MD, offers tips to keep kids healthy as they go back to school.
Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.
OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.
› Verified 6 days ago
| Entity Name | Heart Of Texas Region Mhmr Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639399132 PECOS PAC ID: 9830105105 Enrollment ID: O20060223000214 |
News Archive
Occupational sitting is associated with an increased likelihood of obesity, especially among black women, independent of occupational and leisure time physical activity, finds a new study from the School of Medicine and the Brown School at Washington University in St. Louis.
Theresa Chang and colleagues at Mount Sinai School of Medicine analyzed how alpha-defensin-1 inhibits HIV infection in white blood cells (CD4+ T cells). Defensins have been shown to have anti-HIV activity. The body attempts to protect itself from HIV infection via the innate immune system.
With an uptick in cases of hand, foot and mouth disease in the area, Loyola Medicine pediatric infectious disease specialist Nadia Qureshi, MD, offers tips to keep kids healthy as they go back to school.
Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.
OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.
› Verified 6 days ago
| Entity Name | Murali Veeramachaneni, M.d, P.a |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316282031 PECOS PAC ID: 0345486130 Enrollment ID: O20130424000305 |
News Archive
Occupational sitting is associated with an increased likelihood of obesity, especially among black women, independent of occupational and leisure time physical activity, finds a new study from the School of Medicine and the Brown School at Washington University in St. Louis.
Theresa Chang and colleagues at Mount Sinai School of Medicine analyzed how alpha-defensin-1 inhibits HIV infection in white blood cells (CD4+ T cells). Defensins have been shown to have anti-HIV activity. The body attempts to protect itself from HIV infection via the innate immune system.
With an uptick in cases of hand, foot and mouth disease in the area, Loyola Medicine pediatric infectious disease specialist Nadia Qureshi, MD, offers tips to keep kids healthy as they go back to school.
Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.
OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Murali Veeramachaneni, MD,PA 22 Care Cir, Amarillo, TX 79124-2118 Ph: (806) 354-8300 | Murali Veeramachaneni, MD,PA 22 Care Cir, Amarillo, TX 79124-2118 Ph: (806) 354-8300 |
News Archive
Occupational sitting is associated with an increased likelihood of obesity, especially among black women, independent of occupational and leisure time physical activity, finds a new study from the School of Medicine and the Brown School at Washington University in St. Louis.
Theresa Chang and colleagues at Mount Sinai School of Medicine analyzed how alpha-defensin-1 inhibits HIV infection in white blood cells (CD4+ T cells). Defensins have been shown to have anti-HIV activity. The body attempts to protect itself from HIV infection via the innate immune system.
With an uptick in cases of hand, foot and mouth disease in the area, Loyola Medicine pediatric infectious disease specialist Nadia Qureshi, MD, offers tips to keep kids healthy as they go back to school.
Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.
OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.
› Verified 6 days ago
Dr. W Mitchell Jones Jr., M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2319 Judy Street, Amarillo, TX 79106 Phone: 806-355-0437 | |
Dr. Ruby D Saulog, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1731 Hagy Blvd, Amarillo, TX 79106 Phone: 877-664-6669 Fax: 716-325-9094 | |
Dr. Olga Maria Tolscik, M.D., MPH Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 7620 Wallace Boulevard, Amarillo, TX 79124 Phone: 806-359-5468 | |
Dr. Que Vu Nguyen, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 6010 W Amarillo Blvd, Amarillo, TX 79106 Phone: 806-355-9703 | |
Dr. Mary Lou Montgomery, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 6010 W Amarillo Blvd, Amarillo, TX 79106 Phone: 806-355-9703 | |
Kathryn Elaine Mcneil, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1215 S Coulter St Ste 204, Amarillo, TX 79106 Phone: 806-677-2039 Fax: 806-677-2024 | |
Ruth Elizabeth Grant, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1900 S Coulter St Ste A, Amarillo, TX 79106 Phone: 806-677-7610 Fax: 806-356-0045 |